Gemhexal is a medicine containing the active ingredient(s) gemfibrozil. On this page you will find out more about Gemhexal, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: gemfibrozil
Information for medicine and pack size:
Gemhexal 600 mg film-coated tablet, 60
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Gemhexal is indicated as an adjunct to diet and other therapeutic measures for the following: Severe hypertriglyceridaemia (Type IV and V) in persons who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Dyslipidaemia associated with diabetes. Reduction of risk of coronary heart disease in patients with Type IIa and Type IIb hypercholesterolaemia. Because of potential toxicity, such as malignancy, gall bladder disease, abdominal pain leading to appendicectomy and other abdominal surgeries, an increased incidence in non-coronary mortality, and the 29% increase in all-cause mortality seen with the chemically and pharmacologically related drug, clofibrate, the potential benefits of gemfibrozil in treating Type IIa patients with elevations of LDL cholesterol only is not likely to outweigh the risks. In a subgroup analysis of patients in the Helsinki Heart Study with above median HDL cholesterol values at baseline (greater than 1.2mmol/L), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. NOTE: GEMHEXAL IS INDICATED WHEN EXERCISE, WEIGHT LOSS AND SPECIFIC DIETARY OR OTHER NONDRUG MEASURES SUCH AS LIMITING ALCOHOL INTAKE HAVE FAILED. OTHER MEDICAL DISORDERS SUCH AS HYPOTHYROIDISM AND DIABETES SHOULD BE CONTROLLED AS MUCH AS POSSIBLE. PERIODIC DETERMINATIONS OF SERUM LIPIDS SHOULD BE OBTAINED DURING TREATMENT WITH GEMHEXAL. THE DRUG SHOULD BE WITHDRAWN OR ADDITIONAL THERAPY INSTITUTED IF THE LIPID RESPONSE IS DEEMED INADEQUATE AFTER THREE MONTHS.
Table of characteristics
White, oblong, film-coated tablets
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, film coated|
|Route of administration||Oral|
60 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||2 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.